The Technical Analyst
Erasca, Inc. [ERAS]
Exchange: NASDAQ Global Select Sector: Healthcare Industry: Biotechnology
Erasca, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
0.00% $1.880
/ 25 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 284.81 mill |
| EPS: | -0.830 |
| P/E: | -2.27 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 151.49 mill |
| Avg Daily Volume: | 0.798 mill |
| RATING 2024-04-25 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.27 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -2.27 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.248 (-86.82%) $-1.632 |
| Date: 2024-04-25 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.705 - 2.06 ( +/- 9.31%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-05 | Lim Jonathan E | Buy | 1 500 000 | Stock Option (right to buy) |
| 2024-02-05 | Chacko David M. | Buy | 600 000 | Stock Option (right to buy) |
| 2024-02-05 | Garner Ebun | Buy | 480 000 | Stock Option (right to buy) |
| 2024-02-05 | Morris Shannon | Buy | 535 800 | Stock Option (right to buy) |
| 2024-01-01 | Bristol James Arthur | Buy | 62 747 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 91.08 |
| Last 97 transactions |
| Buy: 49 831 619 | Sell: 16 520 030 |
Forecast:
16:00 - $1.890
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.890
Forecast 2: 16:00 - $1.890
Forecast 3: 16:00 - $1.890
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.880 (0.00% ) |
| Volume | 0.447 mill |
| Avg. Vol. | 0.798 mill |
| % of Avg. Vol | 56.05 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ERAS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:36 | buy | $1.745 | N/A | Active |
|---|
ERAS
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
Latest Press Releases
2024-04-24 16:05:00 - Press Release
Erasca Announces Three Presentations At The 2024 Asco Annual Meeting
Oral presentation will feature updated herkules-3 results for erk1/2 inhibitor eras-007 in combination with encorafenib and cetuximab in brafm colorectal cancer
2024-03-27 20:30:00 - Press Release
Erasca Announces $45 Million Oversubscribed Private Placement Financing
Funding from new and existing investors extends anticipated cash runway into h2 2026 funding from new and existing investors extends anticipated cash runway into h2 2026
2024-03-27 16:01:00 - Press Release
Erasca Reports Fourth Quarter 2023 And Full Year 2023 Business Updates And Financial Results
Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, eras-007, and eras-801
2024-01-03 08:00:00 - Press Release
Erasca To Present At The 42nd Annual J.p. Morgan Healthcare Conference
San diego, jan. 03, 2024 (globe newswire) -- erasca, inc. (nasdaq: eras), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with ras/mapk pathway-driven cancers, today announced its participation in the 42nd annual j.p. morgan healthcare conference being held at the westin st. francis hotel in san francisco, california. jonathan e. lim, m.d., chairman, ceo, and co-founder, will present an overview of the company on tuesday, january 9, 2024 at 9:00 am pacific time in elizabethan room d. dr. lim and david m. chacko, m.d., chief financial officer and chief business officer, will also participate in one-on-one investor meetings.
2023-12-11 08:00:00 - Press Release
Erasca Granted Fda Fast Track Designation For Pan-raf Inhibitor Naporafenib In Patients With Advanced Nras-mutated Melanoma
First-in-class and best-in-class potential in nras-mutated melanoma and other ras/mapk pathway-altered solid tumors naporafenib has been dosed in more than 500 patients to date, establishing its safety, tolerability, and preliminary proof-of-concept in multiple indications pivotal phase 3 seacraft-2 trial initiation in nras-mutated melanoma on track for h1 2024 san diego, dec. 11, 2023 (globe newswire) -- erasca, inc. (nasdaq: eras), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with ras/mapk pathway-driven cancers, today announced that the united states food and drug administration (fda) has granted fast track designation (ftd) to naporafenib in combination with trametinib (mekinist®) for the treatment of adult patients with unresectable or metastatic melanoma who have progressed on, or are intolerant to, an anti‑programmed death-1 (ligand 1) (pd‑(l)1)-based regimen, and whose tumors contain an nras mutation (nrasm)...
Latest News
2024-04-23 13:00:17 - Zacks Investment Research
Erasca (ERAS) Upgraded to Strong Buy: What Does It Mean for the Stock?
Erasca (ERAS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2024-04-23 11:01:12 - Zacks Investment Research
Best Momentum Stocks to Buy for April 23rd
FSM, LPX and ERAS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 23, 2024.
2024-04-23 08:16:06 - Zacks Investment Research
New Strong Buy Stocks for April 23rd
CQP, AL, FSM, ERAS and QUAD have been added to the Zacks Rank #1 (Strong Buy) List on April 23, 2024.
2024-03-29 11:11:07 - Seeking Alpha
Erasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call Transcript
2024-01-03 08:00:00 - GlobeNewsWire
Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 42nd annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis Hotel in San Francisco, California. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, will present an overview of the company on Tuesday, January 9, 2024 at 9:00 am Pacific Time in Elizabethan Room D. Dr. Lim and David M. Chacko, M.D., chief financial officer and chief business officer, will also participate in one-on-one investor meetings.
2023-12-20 13:34:00 - InvestorPlace
3 Penny Stocks You'll Regret Not Buying Soon: December Edition
Although extremely risky, penny stocks can provide tactical value to a portfolio. The risk of losing it all is very real.
2023-12-08 10:07:46 - PennyStocks
4 Penny Stocks To Watch Before Next Week With Big News
Penny stocks, defined as stocks trading under $5 per share, are known for their volatility. Even small pieces of news or unconfirmed rumors can send some penny stocks swinging wildly up or down in price.
2023-12-07 15:36:49 - PennyStocks
3 Penny Stocks To Buy According To Insiders In December
Penny stocks – the cheap stocks trading under $5 per share, offer investors massive upside potential alongside higher risk. Since even incremental price moves translate into huge percentage gains in the stock market, timing entries right can set you up for explosive profits.
2023-11-08 08:00:00 - GlobeNewsWire
Erasca to Present at Upcoming Investor Conferences in November
SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancer, today announced that management will participate in the following investor conferences in November 2023. Management will also participate in one-on-one investor meetings.
2023-09-05 08:00:00 - GlobeNewsWire
Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in a fireside chat on Tuesday, September 12, 2023, at 5:30 pm Eastern Time at the Morgan Stanley 21st Annual Global Healthcare Conference, which is being held at the Sheraton New York Hotel in New York, New York. Management will also participate in one-on-one investor meetings.